Once daily combined inhaled steroid and ultra long-acting bronchodilator prescribing in pediatric asthma: a dual Center retrospective cohort study

Langley, Ross; Dryden, Carol; Westwood, Julie; Anderson, Elaine; Thompson, Alexander; Urquhart, Donald

doi:10.1080/02770903.2019.1702674

Cited by 6 publications

(2 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Such individuals are, thus, difficult asthmatics rather than treatment resistant. Non-adherence with such therapies may result in reduced lung function, increased-interval symptoms, and more frequent/severe Asthma attacks [ 31 ]. Expert panel recommendations on the use of FF/Vi in asthma are depicted in Box 1 .…”

Section: Resultsmentioning

confidence: 99%

ICS/Ultra LABA in the Treatment of Obstructive Airway Diseases: A Consensus of Indian Experts

Dhar

Talwar²,

James³

et al. 2022

ARM

View full text Add to dashboard Cite

Inhaled corticosteroid and ultra-long-acting beta-agonist (ICS/uLABA) combination is a recent advancement in the armamentarium against obstructive airways diseases (OADs). The combination of ICS/uLABA has several advantages, creating a favorable landscape for its utilization. Fluticasone furoate/vilanterol trifenatate (FF/Vi) is one such example of an ICS/uLABA. It offers several benefits from both drugs, such as a convenient once daily dosing schedule; high lipophilicity; high receptor affinity of fluticasone furoate along with high functional selectivity and a quick onset of action of vilanterol. However, the Global Initiative for Asthma (GINA) as well as the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines do not clearly define the positioning of ICS/uLABA compared to conventional ICS/LABAs. There are a few areas of uncertainty especially around the appropriate reliever strategy with ICS/uLABA in Asthma. The current consensus was planned with a group of Indian pulmonology experts to provide more clarity on the potential use of FF/Vi in Asthma and COPD. The clinical statements highlighted in this consensus manuscript address crucial clinical questions revolving around the efficacy and safety of FF/Vi as compared to conventional ICS/LABAs and identify the ideal patient profile for its use. This consensus paper also sheds light upon the appropriate reliever to be used along with FF/Vi in Asthma and the utilization of FF/Vi-based triple therapy in OADs. Expert recommendations mentioned in this paper will serve as guidance to pulmonologists as well as consultant physicians who are involved in providing care to OAD patients and will help them weigh the various factors that need to be taken into account while prescribing ICS/uLABA combination.

show abstract

Section: Resultsmentioning

confidence: 99%

ICS/Ultra LABA in the Treatment of Obstructive Airway Diseases: A Consensus of Indian Experts

Dhar

Talwar²,

James³

et al. 2022

ARM

View full text Add to dashboard Cite

show abstract

“…In such cases, once‐daily regimens may prove beneficial. Although evidence of efficacy of this approach is lacking in children, a recent retrospective review has shown benefit in terms of emergency department attendances and use of oral steroids 4 . If technique is good, then this is an approach that should be considered for adolescents with DA.…”

Section: Personalized Treatments For Severe Asthmamentioning

confidence: 99%